<?xml version="1.0" encoding="utf-8"?> <rss version="2.0"> <channel xmlns:dc="http://dublincore.org/documents/dcmi-namespace/" xmlns:media="http://search.yahoo.com/mrss/"> <title>Cleveland BioLabs, Inc.</title> <link>https://www.globenewswire.com/rssfeed/organization/z-3-QL_X9RkOYxUsazlITQ==</link> <description>Contains the last 20 releases</description> <copyright>Copyright 2017, Cleveland BioLabs, Inc.</copyright> <managingEditor>newsdesk@globenewswire.com (NewsDesk)</managingEditor> <lastBuildDate>Tue, 14 Nov 2017 13:15:00 GMT</lastBuildDate> <webMaster>webmaster@globenewswire.com (Webmaster)</webMaster> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2017/11/14/1230574/0/en/Cleveland-BioLabs-Reports-Third-Quarter-2017-Financial-Results-and-Development-Progress.html</guid> <link>https://www.globenewswire.com/news-release/2017/11/14/1230574/0/en/Cleveland-BioLabs-Reports-Third-Quarter-2017-Financial-Results-and-Development-Progress.html</link> <title>Cleveland BioLabs Reports Third Quarter 2017 Financial Results and Development Progress </title> <description><![CDATA[<p>BUFFALO, NY--(Marketwired - Nov 14, 2017) - <strong> Cleveland BioLabs, Inc.</strong> (<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="CBLI">CBLI</ticker>) today reported financial results and development progress for the third quarter ended September 30, 2017.</p>]]></description> <pubDate>Tue, 14 Nov 2017 13:15 GMT</pubDate> <dc:identifier>1230574</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Cleveland BioLabs, Inc.</dc:contributor> <dc:modified>Wed, 06 Dec 2017 01:58 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2017/08/14/1230570/0/en/Cleveland-BioLabs-Reports-Second-Quarter-2017-Financial-Results-and-Development-Progress.html</guid> <link>https://www.globenewswire.com/news-release/2017/08/14/1230570/0/en/Cleveland-BioLabs-Reports-Second-Quarter-2017-Financial-Results-and-Development-Progress.html</link> <title>Cleveland BioLabs Reports Second Quarter 2017 Financial Results and Development Progress </title> <description><![CDATA[<p>BUFFALO, NY--(Marketwired - Aug 14, 2017) - <strong> Cleveland BioLabs, Inc.</strong> (<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="CBLI">CBLI</ticker>) today reported financial results and development progress for the second quarter ended June 30, 2017.</p>]]></description> <pubDate>Mon, 14 Aug 2017 12:12 GMT</pubDate> <dc:identifier>1230570</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Cleveland BioLabs, Inc.</dc:contributor> <dc:modified>Wed, 06 Dec 2017 01:58 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2017/05/15/1230565/0/en/Cleveland-BioLabs-Reports-First-Quarter-2017-Financial-Results-and-Development-Progress.html</guid> <link>https://www.globenewswire.com/news-release/2017/05/15/1230565/0/en/Cleveland-BioLabs-Reports-First-Quarter-2017-Financial-Results-and-Development-Progress.html</link> <title>Cleveland BioLabs Reports First Quarter 2017 Financial Results and Development Progress </title> <description><![CDATA[<p>BUFFALO, NY--(Marketwired - May 15, 2017) - <strong>Cleveland BioLabs, Inc. </strong>(<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="CBLI">CBLI</ticker>) today reported financial results and development progress for the first quarter ended March 31, 2017. </p>]]></description> <pubDate>Mon, 15 May 2017 11:30 GMT</pubDate> <dc:identifier>1230565</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Cleveland BioLabs, Inc.</dc:contributor> <dc:modified>Wed, 06 Dec 2017 01:58 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2017/04/17/1230559/0/en/Cleveland-BioLabs-Announces-Commencement-of-In-Vivo-Biocomparability-Study.html</guid> <link>https://www.globenewswire.com/news-release/2017/04/17/1230559/0/en/Cleveland-BioLabs-Announces-Commencement-of-In-Vivo-Biocomparability-Study.html</link> <title>Cleveland BioLabs Announces Commencement of In Vivo Biocomparability Study </title> <description><![CDATA[<p>BUFFALO, NY--(Marketwired - Apr 17, 2017) - <strong> Cleveland BioLabs, Inc.</strong> (<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="CBLI">CBLI</ticker>) today announced that the U.S. Food and Drug Administration (FDA) has completed its review of a side-by-side analytical comparison of two formulations of entolimod. The FDA agreed with CBLI that these data indicate the <em>in vitro</em> analytical comparability of the formulations. Based on the outcome of its review, the FDA has provided CBLI with its consent for initiation of an <em>in vivo</em> biocomparability study of these formulations in non-human primates (NHP).</p>]]></description> <pubDate>Mon, 17 Apr 2017 11:36 GMT</pubDate> <dc:identifier>1230559</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Cleveland BioLabs, Inc.</dc:contributor> <dc:modified>Wed, 06 Dec 2017 01:58 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2017/04/17/1230562/0/en/Cleveland-BioLabs-Announces-European-Medicines-Agency-Positive-Opinion-Regarding-the-Entolimod-Pediatric-Investigation-Plan.html</guid> <link>https://www.globenewswire.com/news-release/2017/04/17/1230562/0/en/Cleveland-BioLabs-Announces-European-Medicines-Agency-Positive-Opinion-Regarding-the-Entolimod-Pediatric-Investigation-Plan.html</link> <title>Cleveland BioLabs Announces European Medicines Agency Positive Opinion Regarding the Entolimod Pediatric Investigation Plan </title> <description><![CDATA[<p>BUFFALO, NY--(Marketwired - Apr 17, 2017) - <strong> Cleveland BioLabs, Inc.</strong> (<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="CBLI">CBLI</ticker>) today announced that the European Medicines Agency (EMA) has accepted the company's pediatric investigation plan (PIP), paving the way for submission of a Marketing Authorization Application (MAA) for entolimod as a medical radiation countermeasure. </p>]]></description> <pubDate>Mon, 17 Apr 2017 11:30 GMT</pubDate> <dc:identifier>1230562</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Cleveland BioLabs, Inc.</dc:contributor> <dc:modified>Wed, 06 Dec 2017 01:58 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2017/04/11/1230554/0/en/Cleveland-BioLabs-Announces-Webcast-of-Annual-Meeting.html</guid> <link>https://www.globenewswire.com/news-release/2017/04/11/1230554/0/en/Cleveland-BioLabs-Announces-Webcast-of-Annual-Meeting.html</link> <title>Cleveland BioLabs Announces Webcast of Annual Meeting </title> <description><![CDATA[<p>BUFFALO, NY--(Marketwired - Apr 11, 2017) - <strong> Cleveland BioLabs, Inc. </strong>(<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="CBLI">CBLI</ticker>) today announced that the Company will webcast its 2017 Annual Meeting of Stockholders on April 21, 2017 at its headquarters in Buffalo, NY. </p>]]></description> <pubDate>Tue, 11 Apr 2017 21:00 GMT</pubDate> <dc:identifier>1230554</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Cleveland BioLabs, Inc.</dc:contributor> <dc:modified>Wed, 06 Dec 2017 01:58 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2017/02/22/1230551/0/en/Cleveland-BioLabs-Reports-2016-Financial-Results-and-Development-Progress.html</guid> <link>https://www.globenewswire.com/news-release/2017/02/22/1230551/0/en/Cleveland-BioLabs-Reports-2016-Financial-Results-and-Development-Progress.html</link> <title>Cleveland BioLabs Reports 2016 Financial Results and Development Progress </title> <description><![CDATA[<p>BUFFALO, NY--(Marketwired - Feb 22, 2017) - <strong>Cleveland BioLabs, Inc. </strong>(<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="CBLI">CBLI</ticker>) today reported financial results and development progress for the fourth quarter and year ended December 31, 2016. </p>]]></description> <pubDate>Wed, 22 Feb 2017 21:15 GMT</pubDate> <dc:identifier>1230551</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Cleveland BioLabs, Inc.</dc:contributor> <dc:modified>Wed, 06 Dec 2017 01:58 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2016/11/14/1230546/0/en/Cleveland-BioLabs-Reports-Third-Quarter-2016-Financial-Results-and-Development-Progress.html</guid> <link>https://www.globenewswire.com/news-release/2016/11/14/1230546/0/en/Cleveland-BioLabs-Reports-Third-Quarter-2016-Financial-Results-and-Development-Progress.html</link> <title>Cleveland BioLabs Reports Third Quarter 2016 Financial Results and Development Progress </title> <description><![CDATA[<p>BUFFALO, NY--(Marketwired - Nov 14, 2016) - <strong> Cleveland BioLabs, Inc.</strong> (<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="CBLI">CBLI</ticker>) today reported financial results and development progress for the third quarter ended September 30, 2016. </p>]]></description> <pubDate>Mon, 14 Nov 2016 12:30 GMT</pubDate> <dc:identifier>1230546</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Cleveland BioLabs, Inc.</dc:contributor> <dc:modified>Wed, 06 Dec 2017 01:58 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2016/10/11/1230543/0/en/Cleveland-BioLabs-Announces-a-1-1-Million-Cost-Realignment-With-the-Department-of-Defense.html</guid> <link>https://www.globenewswire.com/news-release/2016/10/11/1230543/0/en/Cleveland-BioLabs-Announces-a-1-1-Million-Cost-Realignment-With-the-Department-of-Defense.html</link> <title>Cleveland BioLabs Announces a $1.1 Million Cost Realignment With the Department of Defense </title> <description><![CDATA[<p>BUFFALO, NY--(Marketwired - Oct 11, 2016) - <strong>Cleveland BioLabs, Inc. </strong>(<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="CBLI">CBLI</ticker>) today announced that the Department of Defense (DoD) has modified its Joint Warfighter Medical Research Program (JWMRP) contract award number W81XWH-15-C-0101 with CBLI valued at up to $9.2 million which supports further development of entolimod as a medical radiation countermeasure. </p>]]></description> <pubDate>Tue, 11 Oct 2016 12:45 GMT</pubDate> <dc:identifier>1230543</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Cleveland BioLabs, Inc.</dc:contributor> <dc:modified>Wed, 06 Dec 2017 01:58 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2016/08/15/1230542/0/en/Cleveland-BioLabs-Reports-Second-Quarter-2016-Financial-Results-and-Development-Progress.html</guid> <link>https://www.globenewswire.com/news-release/2016/08/15/1230542/0/en/Cleveland-BioLabs-Reports-Second-Quarter-2016-Financial-Results-and-Development-Progress.html</link> <title>Cleveland BioLabs Reports Second Quarter 2016 Financial Results and Development Progress </title> <description><![CDATA[<p>BUFFALO, NY--(Marketwired - Aug 15, 2016) - <strong> Cleveland BioLabs, Inc.</strong> (<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="CBLI">CBLI</ticker>) today reported financial results and development progress for the second quarter ended June 30, 2016. </p>]]></description> <pubDate>Mon, 15 Aug 2016 12:30 GMT</pubDate> <dc:identifier>1230542</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Cleveland BioLabs, Inc.</dc:contributor> <dc:modified>Wed, 06 Dec 2017 01:58 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2016/07/12/1230540/0/en/Cleveland-BioLabs-Announces-Board-Resignations.html</guid> <link>https://www.globenewswire.com/news-release/2016/07/12/1230540/0/en/Cleveland-BioLabs-Announces-Board-Resignations.html</link> <title>Cleveland BioLabs Announces Board Resignations </title> <description><![CDATA[<p>BUFFALO, NY--(Marketwired - Jul 12, 2016) - <strong>Cleveland BioLabs, Inc. </strong>(<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="CBLI">CBLI</ticker>) today announced that Board Chair Richard McGowan and Audit Committee Chair James Antal resigned from the company's Board of Directors, effective last Friday, July 8. Their resignations were predicated on the Board's decision not to renew its policy of directors' and officers' liability insurance as a cost-saving measure. CBLI will seek to fill these Board vacancies as soon as possible.</p>]]></description> <pubDate>Tue, 12 Jul 2016 13:00 GMT</pubDate> <dc:identifier>1230540</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Cleveland BioLabs, Inc.</dc:contributor> <dc:modified>Wed, 06 Dec 2017 01:58 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2016/05/16/1230537/0/en/Cleveland-BioLabs-Reports-First-Quarter-2016-Financial-Results-and-Development-Progress.html</guid> <link>https://www.globenewswire.com/news-release/2016/05/16/1230537/0/en/Cleveland-BioLabs-Reports-First-Quarter-2016-Financial-Results-and-Development-Progress.html</link> <title>Cleveland BioLabs Reports First Quarter 2016 Financial Results and Development Progress </title> <description><![CDATA[<p>BUFFALO, NY--(Marketwired - May 16, 2016) - <strong> Cleveland BioLabs, Inc. </strong>(<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="CBLI">CBLI</ticker>) today reported financial results and development progress for the first quarter ended March 31, 2016. </p>]]></description> <pubDate>Mon, 16 May 2016 11:30 GMT</pubDate> <dc:identifier>1230537</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Cleveland BioLabs, Inc.</dc:contributor> <dc:modified>Wed, 06 Dec 2017 01:58 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2016/04/04/1230535/0/en/Cleveland-BioLabs-Announces-Webcast-of-Annual-Meeting.html</guid> <link>https://www.globenewswire.com/news-release/2016/04/04/1230535/0/en/Cleveland-BioLabs-Announces-Webcast-of-Annual-Meeting.html</link> <title>Cleveland BioLabs Announces Webcast of Annual Meeting </title> <description><![CDATA[<p>BUFFALO, NY--(Marketwired - Apr 4, 2016) - <strong> Cleveland BioLabs, Inc. </strong>(<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="CBLI">CBLI</ticker>) today announced that the Company will webcast its 2016 Annual Meeting of Stockholders on April 14, 2016 at its headquarters in Buffalo, NY. </p>]]></description> <pubDate>Mon, 04 Apr 2016 11:30 GMT</pubDate> <dc:identifier>1230535</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Cleveland BioLabs, Inc.</dc:contributor> <dc:modified>Wed, 06 Dec 2017 01:58 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2016/03/16/1230532/0/en/Cleveland-BioLabs-Provides-Update-on-Pre-EUA-Review-of-Entolimod-as-Radiation-Countermeasure.html</guid> <link>https://www.globenewswire.com/news-release/2016/03/16/1230532/0/en/Cleveland-BioLabs-Provides-Update-on-Pre-EUA-Review-of-Entolimod-as-Radiation-Countermeasure.html</link> <title>Cleveland BioLabs Provides Update on Pre-EUA Review of Entolimod as Radiation Countermeasure </title> <description><![CDATA[<p>BUFFALO, NY--(Marketwired - Mar 16, 2016) - <strong> Cleveland BioLabs, Inc. </strong>(<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="CBLI">CBLI</ticker>) today announced an update on the regulatory review of its pre-Emergency Use Authorization (pre-EUA) submission for entolimod as a radiation countermeasure following the receipt of minutes from a recent meeting with the U.S. Food and Drug Administration (FDA).</p>]]></description> <pubDate>Wed, 16 Mar 2016 18:00 GMT</pubDate> <dc:identifier>1230532</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Cleveland BioLabs, Inc.</dc:contributor> <dc:modified>Wed, 06 Dec 2017 01:58 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2016/02/22/1230530/0/en/Cleveland-BioLabs-Reports-2015-Financial-Results-and-Development-Progress.html</guid> <link>https://www.globenewswire.com/news-release/2016/02/22/1230530/0/en/Cleveland-BioLabs-Reports-2015-Financial-Results-and-Development-Progress.html</link> <title>Cleveland BioLabs Reports 2015 Financial Results and Development Progress </title> <description><![CDATA[<p>BUFFALO, NY--(Marketwired - Feb 22, 2016) - <strong>Cleveland BioLabs, Inc. </strong>(<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="CBLI">CBLI</ticker>) today reported financial results and development progress for the fourth quarter and year ended December 31, 2015. </p>]]></description> <pubDate>Mon, 22 Feb 2016 12:30 GMT</pubDate> <dc:identifier>1230530</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Cleveland BioLabs, Inc.</dc:contributor> <dc:modified>Wed, 06 Dec 2017 01:58 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2016/02/09/1230528/0/en/Entolimod-Shown-to-Suppress-Metastasis-and-Induce-Immunity-by-Stimulating-NK-Dendritic-CD8-T-cell-Axis-in-Studies-by-Cleveland-BioLabs-and-Roswell-Park-Cancer-Institute.html</guid> <link>https://www.globenewswire.com/news-release/2016/02/09/1230528/0/en/Entolimod-Shown-to-Suppress-Metastasis-and-Induce-Immunity-by-Stimulating-NK-Dendritic-CD8-T-cell-Axis-in-Studies-by-Cleveland-BioLabs-and-Roswell-Park-Cancer-Institute.html</link> <title>Entolimod Shown to Suppress Metastasis and Induce Immunity by Stimulating NK-Dendritic-CD8+ T cell Axis in Studies by Cleveland BioLabs and Roswell Park Cancer Institute </title> <description><![CDATA[<p>BUFFALO, NY--(Marketwired - Feb 9, 2016) - <strong> Cleveland BioLabs, Inc. </strong>(<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="CBLI">CBLI</ticker>) and <strong>Roswell Park Cancer Institute (RPCI) </strong>today announced the publication of studies elucidating immunotherapeutic mechanisms through which entolimod suppresses metastasis. The data were published in <em>Proceedings of the National Academy of Sciences of the United States of America</em> (<em>PNAS),</em> the official journal of the United States National Academy of Sciences, based on studies conducted by scientists at RPCI and CBLI. </p>]]></description> <pubDate>Tue, 09 Feb 2016 12:30 GMT</pubDate> <dc:identifier>1230528</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Cleveland BioLabs, Inc.</dc:contributor> <dc:modified>Wed, 06 Dec 2017 01:58 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2016/02/02/1230525/0/en/Cleveland-BioLabs-Announces-Start-of-Colorectal-Cancer-Study-of-Entolimod-in-Russian-Federation.html</guid> <link>https://www.globenewswire.com/news-release/2016/02/02/1230525/0/en/Cleveland-BioLabs-Announces-Start-of-Colorectal-Cancer-Study-of-Entolimod-in-Russian-Federation.html</link> <title>Cleveland BioLabs Announces Start of Colorectal Cancer Study of Entolimod in Russian Federation </title> <description><![CDATA[<p>BUFFALO, NY--(Marketwired - Feb 2, 2016) - <strong> Cleveland BioLabs, Inc.</strong> (<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="CBLI">CBLI</ticker>) today announced the initiation of a Phase 2, single-blind, randomized, placebo-controlled clinical study of the safety and tolerability of entolimod as a neo-adjuvant therapy in treatment-naïve patients with primary colorectal cancer who are recommended for surgery. </p>]]></description> <pubDate>Tue, 02 Feb 2016 13:00 GMT</pubDate> <dc:identifier>1230525</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Cleveland BioLabs, Inc.</dc:contributor> <dc:modified>Wed, 06 Dec 2017 01:58 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2016/01/26/1230523/0/en/Cleveland-BioLabs-Announces-Start-of-Phase-2-Study-of-CBLB612-in-Russian-Federation.html</guid> <link>https://www.globenewswire.com/news-release/2016/01/26/1230523/0/en/Cleveland-BioLabs-Announces-Start-of-Phase-2-Study-of-CBLB612-in-Russian-Federation.html</link> <title>Cleveland BioLabs Announces Start of Phase 2 Study of CBLB612 in Russian Federation </title> <description><![CDATA[<p>BUFFALO, NY--(Marketwired - Jan 26, 2016) - <strong>Cleveland BioLabs, Inc. </strong>(<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="CBLI">CBLI</ticker>) today announced the start of dosing in a Phase 2, randomized, placebo-controlled clinical study of CBLB612 as myelosuppressive prophylaxis in patients with breast cancer receiving doxorubicin-cyclophosphamide chemotherapy.</p>]]></description> <pubDate>Tue, 26 Jan 2016 12:30 GMT</pubDate> <dc:identifier>1230523</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Cleveland BioLabs, Inc.</dc:contributor> <dc:modified>Wed, 06 Dec 2017 01:58 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2016/01/21/1230521/0/en/Cleveland-BioLabs-Attains-Orphan-Drug-Status-From-the-EMA-for-Entolimod-as-a-Radiation-Countermeasure.html</guid> <link>https://www.globenewswire.com/news-release/2016/01/21/1230521/0/en/Cleveland-BioLabs-Attains-Orphan-Drug-Status-From-the-EMA-for-Entolimod-as-a-Radiation-Countermeasure.html</link> <title>Cleveland BioLabs Attains Orphan Drug Status From the EMA for Entolimod as a Radiation Countermeasure </title> <description><![CDATA[<p>BUFFALO, NY--(Marketwired - Jan 21, 2016) - <strong> Cleveland BioLabs, Inc. </strong>(<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="CBLI">CBLI</ticker>), today announced that entolimod has been granted orphan drug status by the European Medicines Agency (EMA) for treatment of acute radiation syndrome. Acute radiation syndrome comprises serious bone marrow, gastrointestinal, and other toxicities arising from exposure to high doses of radiation. </p>]]></description> <pubDate>Thu, 21 Jan 2016 12:30 GMT</pubDate> <dc:identifier>1230521</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Cleveland BioLabs, Inc.</dc:contributor> <dc:modified>Wed, 06 Dec 2017 01:58 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2015/12/22/1230519/0/en/Cleveland-BioLabs-and-Rusnano-Make-Additional-Investments-in-Panacela.html</guid> <link>https://www.globenewswire.com/news-release/2015/12/22/1230519/0/en/Cleveland-BioLabs-and-Rusnano-Make-Additional-Investments-in-Panacela.html</link> <title>Cleveland BioLabs and Rusnano Make Additional Investments in Panacela </title> <description><![CDATA[<p>BUFFALO, NY--(Marketwired - Dec 22, 2015) - <strong> Cleveland BioLabs, Inc.</strong> (<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="CBLI">CBLI</ticker>) today announced that through a series of transactions and in cooperation with Open Joint Stock Company RUSNANO (Rusnano) it has recapitalized Panacela Labs, Inc. (Panacela), a majority-owned joint venture. </p>]]></description> <pubDate>Tue, 22 Dec 2015 12:30 GMT</pubDate> <dc:identifier>1230519</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Cleveland BioLabs, Inc.</dc:contributor> <dc:modified>Wed, 06 Dec 2017 01:58 GMT</dc:modified> </item> </channel> </rss>